Efficacy and Toxicity of Alternative Radiation Treatment Schemes for Patients With Hematologic Malignancies: A Collaborative ILROG COVID Era Report

Abstract

\n Purpose/Objective(s)\n The COVID19 pandemic required radiation oncologists (ROs) to consider shorter treatment courses to minimize patient and staff exposure and conserve healthcare resources. Hematologic ROs adopted hypofractionated radiation therapy (hRT) regimens according to guidelines published by the International Lymphoma Radiation Oncology Group (ILROG). We report for the first time the preliminary efficacy and toxicity of these novel hypofractionated regimens in the treatment of hematologic malignancies.\n \n Materials/Methods\n We conducted a multicenter, multinational retrospective study under the direction of the ILROG. All patients receiving hRT according to ILROG guidelines from 1/1/2020 to 8/31/2020 were included. Patient and treatment details were abstracted from separate institutional databases. Toxicity was graded using CTCAE v5.0.\n \n Results\n Ninety-three patients from 4 institutions treated with 114 RT courses were included. Patient and treatment details are displayed in Table 1. Median follow up for the cohort was 179 days, and 77 patients (82%) were alive at last follow up. Maximal toxicity experienced by patients included Grade 1 (n\u202f=\u202f16), Grade 2 (n\u202f=\u202f1) and Grade 3 (n\u202f=\u202f1) toxicities. Of 80 sites with response assessment within the RT field, 69% of patients achieved a complete response (n\u202f=\u202f55), 20% partial response (n\u202f=\u202f16), 9% stable disease (n\u202f=\u202f7), and 2% progressive disease (n\u202f=\u202f2). No COVID19 infections during or after RT have been documented in this patient cohort.\n \n Conclusion\n HRT according to ILROG guidelines resulted in low rates of acute toxicity and reasonable short-term treatment efficacy. Longer follow up and comparison with control groups is needed to draw more definitive conclusions and will be presented at the Annual Meeting.\n